Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 5/20 | 0.37 |
| ▸ | MMP2 | P08253 | 4/20 | 0.37 |
| ▸ | MMP8 | P22894 | 3/20 | 0.37 |
| ▸ | MMP13 | P45452 | 3/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.34 |
| ▸ | HTR6 | P50406 | 2/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.33 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.31 |
| ▸ | OXTR | P30559 | 1/20 | 0.31 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2197207 | 0.89 | DHODH (0.32) | GRM4 | |
| SCHEMBL1835212 | 0.89 | MMP2 (0.35) | MMP9MMP2MMP8MMP13GSK3B | |
| SCHEMBL2191647 | 0.88 | MMP2 (0.35) | MMP9MMP2MMP8MMP13GSK3B | |
| SCHEMBL1835214 | 0.88 | MMP2 (0.35) | MMP9MMP2MMP8MMP13GSK3B | |
| SCHEMBL2407107 | 0.86 | DHODH (0.33) | HTR6PTGDR2 | |
| SCHEMBL2199163 | 0.85 | GSK3B (0.38) | MMP9MMP2MMP8MMP13GSK3B | |
| SCHEMBL5005965 | 0.84 | MET (0.44) | MMP9MMP2MMP8MMP13NFE2L2 | |
| SCHEMBL5008551 | 0.84 | NFE2L2 (0.34) | MMP9MMP2MMP8MMP13NFE2L2 | |
| SCHEMBL1837519 | 0.84 | GSK3B (0.37) | MMP9MMP2MMP8MMP13GSK3B | |
| Hydrochloric Acid SCHEMBL1833777 | 0.83 | GSK3B (0.36) | MMP9MMP2MMP8MMP13GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993598-B2 | Pyrrole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-31 | — | — | US | disclosed |
| US-8969387-B2 | Pyrrole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140031393-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8592597-B2 | Pyrrole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-26 | — | — | US | disclosed |
| EP-2318390-B1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2013-05-01 | — | — | EP | disclosed |
| US-20110172275-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| WO-2010024451-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | WO | disclosed |
| US-20100056577-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056577-A1 | PYRROLE COMPOUNDS | PRLHR, C1R, C1S | MMP9 3837/4885MMP2 4146/4885MMP8 4519/4885 |
| US-20140031393-A1 | PYRROLE COMPOUNDS | PRLHR, C1R, C1S | MMP9 3837/4885MMP2 4146/4885MMP8 4519/4885 |
| US-20110172275-A1 | PYRROLE COMPOUNDS | PRLHR, C1R, C1S | MMP9 3837/4885MMP2 4146/4885MMP8 4519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.